| antidepressants |
drug |
22 |
14 |
antidepressant, antidepressant medication, antidepressant treatments, antidepressant use, antidepressants |
| antipsychotics |
drug |
21 |
11 |
ATC code N05A, anti-psychotics, antipsychotic medication, antipsychotics, olanzapine (5 mg) |
| Anti-social personality disorder |
phenotype |
2 |
1 |
anti-social personality disorder |
| antisocial personality disorder |
phenotype |
87 |
47 |
AASB, APD, ASB, ASP, ASPD, Antisocial PD, Antisocial men, Antisocial personality disorder, Antisociality, DSM-IV Antisocial Personality Disorder, antisocial, antisocial PD, antisocial actions, antisocial behavior, antisocial behavior factor, antisocial behavior items, antisocial behavior personality disorder, antisocial behavior problems, antisocial behavioral syndromes, antisocial behaviors, antisocial behaviour, antisocial conduct, antisocial lifestyle, antisocial personality, antisocial personality disorder, antisocial problems, antisocial symptoms, antisocial traits, antisociality, comorbid antisocial behavior, long-term antisocial behavior, negative outcomes |
| anxiety |
phenotype |
151 |
97 |
ANX, Anxiety disorders, F40-F43, MA-induced anxiety disorder, PTSD-related anxiety, Spielberger State-Trait Anxiety Inventory, anxiety, anxiety disorder, anxiety disorder alone, anxiety disorders, anxiety scores, anxiety symptoms, anxiety-like, anxiety-related disorder, anxiogenic behavior, anxiogenic withdrawal, anxiogenic-like effects, anxiolytic effect, anxiolytic properties, anxious phenotype, anxious symptomatology, anxious symptoms, basal anxiety, co-occurring anxiety disorders, comorbid anxiety, comorbid anxiety disorder, comorbid anxiety disorders, correlates of anxiety, elevated anxiety, elevated anxiety level, feeling nervous or anxious, independent anxiety disorder, lifetime DSM-III-R anxiety disorders, lifetime DSM-IV anxiety disorder, pregnancy-related anxiety, state-related changes in anxiety |
| Anxiety/depression |
phenotype |
4 |
3 |
|
| anxiety-like behavior |
phenotype |
15 |
10 |
anxiety, anxiety behavior, anxiety-like, anxiety-like behavior |
| anxiety symptoms |
phenotype |
8 |
5 |
Anxiety, anxiety, anxiety symptoms during withdrawal, anxious symptoms |
| anxiolytic effect |
phenotype |
8 |
4 |
anxiolytic, anxiolytic effect |
| AP |
drug |
3 |
53 |
Alcohol Problems, alcohol problems |
| AP-1 |
drug |
2 |
— |
FOS/JUN |
| AP-2 |
drug |
2 |
2 |
AP2, AP‑2, Adaptor protein complex 2, adaptor complex (AP), adaptor complex 2, adaptor protein complex 2 |
| APC |
drug |
2 |
2 |
|
| APOC3 |
gene |
2 |
2 |
Apolipoprotein C-III |
| apoE |
gene |
25 |
17 |
APOE, APOE susceptibility gene, APOE ε4, APOE-4, APOE-4 allele, ApoE, Apolipoprotein E, apoE, apoE4/4, apolipoprotein E, apolipoprotein E APOE |
| apoE4 |
gene |
3 |
2 |
APOE ε4, ApoE4/4, apoE4, apoE4/4 genotype, apolipoprotein E epsilon 4 allele |
| APOE-4 carriers |
cohort |
2 |
2 |
|
| APOE ε4 |
gene |
5 |
4 |
APOE ε4 risk allele, APOE4, ApoE ε4, allele 4, apoE4, ε4, ε4 allele |
| APOE ε4 allele |
gene |
3 |
3 |
APOE*ε4, APOE-4, ApoE 4 allele, ε4, ε4 allele |
| apoptosis |
phenotype |
31 |
19 |
OPC death, apoptosis, cell death, natural apoptosis, oligodendrocyte death |
